Michel Corban, MD
Interventional Cardiology · Tucson, AZNPI 1699112268
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Philips North America LLC accounts for 84.2% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2024 at $18,888 and has fallen 94.6% since, to $1,021 in 2025.
Across 122 payments — averaging $219.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$23K
- Boston Scientific$1K
- Edwards Lifesciences$670
- Shockwave Medical, Inc$406
- Abiomed$350
- Abbott$312
- plus $1K from 10 others
Across 12 payments — averaging $6574.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$58K
- Neovasc Medical Inc$21K
- Abiomed$50
What the payments were for
- Consulting fees$12,60047%
- Travel & lodging$8,17131%
- Food & beverage$5,95222%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 35 | $22,505 |
| Boston Scientific | 30 | $1,054 |
| Edwards Lifesciences | 13 | $670 |
| Shockwave Medical, Inc | 19 | $406 |
| Abiomed | 3 | $350 |
| Abbott | 2 | $312 |
| Medtronic | 8 | $300 |
| Baxter Healthcare | 2 | $221 |
| Novartis | 3 | $212 |
| Cardiovascular Systems Inc. | 1 | $170 |
| Teleflex LLC | 1 | $145 |
| Penumbra, Inc. | 1 | $139 |
| Inari Medical, Inc. | 1 | $137 |
| Amgen | 1 | $64 |
| Terumo Medical Corporation | 1 | $30 |
| Neovasc Medical Inc | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (9520) IGT Devices Undivided$19,945
- (6554) Peripheral Vascular Undivided$488
- (6494) Flowire$437
- COROFLOW$312
- Impella$254
- WATCHMAN Access System$253
- (P88) IGT Devices FM$239
- IGT Systems Und$228
- (6571) Eagle Eye$206
- Coronary Orbital Atherectomy System$170
- (6574) Coronary Other$158
- GUIDELINER$145
- Indigo System$139
- FLOWTRIEVER CATHETER, S$137
- CT THROMBECTOMY SYSTEM KIT$137
- INSPIRIS RESILIA aortic valve$127
- PREVELEAK$118
- COREVALVE EVOLUT R$117
- MITRIS RESILIA Mitral Valve$110
- (6496) FM Other$107
How this compares
$26,723 in reported general payments places this provider in the 75th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 57 | $88,440 |
| FarxigaDapagliflozin Propanediol | 23 | $36,138 |
| BrilintaTicagrelor | 26 | $29,310 |
| EntrestoSacubitril/Valsartan | 12 | $20,716 |
| XareltoRivaroxaban | 13 | $20,523 |
| JardianceEmpagliflozin | 16 | $15,706 |
| Repatha SyringeEvolocumab | 12 | $11,241 |
| Ranolazine ErRanolazine | 19 | $4,665 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 87 | $3,170 |
| Atorvastatin Calcium | 187 | $2,018 |
| Metoprolol Succinate | 114 | $1,551 |
| Nitroglycerin | 30 | $1,421 |
| Losartan Potassium | 101 | $1,305 |
| ClopidogrelClopidogrel Bisulfate | 92 | $1,227 |
| Rosuvastatin Calcium | 92 | $1,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $212 | $20,71612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Tucson
- Thomas WaggonerTucson$617K
- Kapildeo LotunTucson$365K
- Neil GheewalaTucson$141K
- Dexter de LeonTucson$74K
- William ThomasTucson$56K
- Ranjith ShettyTucson$50K
- Santiago RamirezTucson$45K
- Sulaiman RathoreTucson$32K
- Sundeep ShenoyTucson$24K
- Paul SorajjaPhoenix$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.